News Merck and Pfizer stop third Bavencio ovarian cancer trial Merck and Pfizer are discontinuing the Phase III JAVELIN Ovarian PARP 100 study evaluating Bavencio (avelumab) in advanced ovarian cancer, signalling yet more disappointment for the PD-L1 immuno
News Cell Mogrify gets £420k funding for regenerative cell therap... UK cell therapy company Cell Mogrify has been awarded £420,000 funding from Innovate UK to accelerate its data-driven cell conversion programmes.
Partner Content Partner Content Immuno-Oncology 2018 News: MHRA Interview and New Speaker Im... Just Over 1 Week Until Immuno-Oncology 2018 Commences
Partner Content Partner Content MHRA, Pfizer, Autolus and Tusk Theraputics Sign Up for Immun... MHRA, Pfizer & Autolus Sign Up for Immuno-Oncology 2018
Sales & Marketing Biotech is back, with Craig Ackerman In Philadelphia this month, pharmaphorum spoke with Craig Ackerman, a partner at the Alexander Group, about launches, AI best practices, and more.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
